VivoSeq
Musculoskeletal

Lumbar Spinal Stenosis

5

Pipeline Programs

3

Active Trials

2

Companies Involved

Lumbar Spinal Stenosis is an early-stage landscape with 5 programs across 2 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Stryker Instruments. 2 therapies are approved.

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

67/100

Attrition Rate

22/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Trial Status

9

clinical trials

Completed4 · 44%
Withdrawn1 · 11%
Terminated1 · 11%
Active, not recruiting1 · 11%
Recruiting1 · 11%
Not yet recruiting1 · 11%

Trial Activity

9 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)